Celldex Therapeutics Inc.


Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Analysts See Recent Data from Celldex Therapeutics, Inc. (CLDX) and Ariad Pharmaceuticals, Inc. (ARIA) Through Rose Colored Glasses

Healthcare analysts expressed their views on drug makers Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Ariad Pharmaceuticals, Inc.

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced new safety and immune response data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort …

Analysts Have Mixed Views on Celgene Corporation (CELG) and Celldex Therapeutics, Inc. (CLDX) Following Recent Announcements

Celgene Corporation (NASDAQ:CELG) announced an ANDA for its drug Abraxane yesterday. Due to the complex circumstances and probable litigation, one analyst predicts a …

Analysts Shine Light On Two Volatile Healthcare Stocks: Celldex Therapeutics, Inc. (CLDX), Invivo Therapeutics Holdings Corp (NVIV)

As two biotech companies continue announce pipeline progressions, for better or worse, analysts weigh in on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Invivo Therapeutics …

Monday Morning’s Insights: Celldex Therapeutics, Inc. (CLDX), Linn Energy LLC (LINE), LinnCo LLC (LNCO)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shareholders are having a rough morning as the company’s shares are collapsing, down 51% in pre-market trading Monday, after the company announced that …

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Concludes RINTEGA Trial

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation …

Analysts Provide Positive Outlook On Two Pharmaceutical Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Celldex Therapeutics,Inc. (CLDX)

Analysts are bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) as Valeant’s CEO has returned from sick leave and …

Biotech Roundup: Celldex Therapeutics, Inc. (CLDX), Keryx Biopharmaceuticals (KERX), BioDelivery Sciences International, Inc. (BDSI)

Biotech stocks are notoriously volatile as a pipeline update or FDA announcement can instantly send share prices through the roof. Below, analysts weigh …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts